Cite
MLA Citation
Philip G Conaghan et al.. “Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study.” Lancet, vol. 5, 2023, pp. e263–e273. http://access.bl.uk/ark:/81055/vdc_100184745900.0x000001